Review
BibTex RIS Cite

Kanserde Hedefe Yönelik Tedavi: PI3K/Akt/mTOR İnhibitörleri

Year 2022, Volume: 31 Issue: 1, 15 - 20, 31.03.2022
https://doi.org/10.17827/aktd.1001226

Abstract

Kanserler genel olarak çoklu genetik ve epigenetik anormallikler içermekte fakat birkaç anahtar gen sayesinde malign fenotip ve hücresel sağkalımın devamlılığı sağlanmaktadır. PI3K/Akt/mTOR yolağı önemli birçok fizyolojik olaylarda rol alan merkezi bir sinyal akım sistemidir. PI3K/Akt/mTOR yolağı birçok tümör çeşidi tarafından kullanıldığından bu yolağa karşı kullanılan inhibitörlerin geniş bir terapötik etkinliğinin olabileceği düşünülmektedir. Tekli tedavide bu inhibitörlerin hiçbiri ile faz 1 çalışmalarda önemli cevap oranları elde edilememiş olup yüksek dozların kısa sürelerde verilmesi ve değişik yolaklara etkili olabilecek ilaçların kombine edilmesi gibi diğer seçenekler araştırılmaktadır.


References

  • 1. Timothy A Yap, Michelle D Garrett, Mike I Walton, Florence Raynaud, Johann S de Bono, Paul Workman. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology, 2008;8:393-412.
  • 2. Weinstein IB, Joe AK: Mechanisms of disease: oncogene addiction — a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
  • 3. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.

Targeted Cancer Therapy: PI3K/Akt/mTOR Inhibitors

Year 2022, Volume: 31 Issue: 1, 15 - 20, 31.03.2022
https://doi.org/10.17827/aktd.1001226

Abstract

Cancers generally contain multiple genetic and epigenetic abnormalities, but several key genes maintain the malignant phenotype and cellular survival. The PI3K/Akt/mTOR pathway is a central signaling system that plays a role in many important physiological events. Since the PI3K/Akt/mTOR pathway is used by many tumor types, it is thought that inhibitors used against this pathway may have a wide therapeutic efficacy. Significant response rates could not be obtained in phase 1 studies with any of the agents in monotherapy, and other options are being investigated by administering high doses in short periods and combining drugs that may affect different pathways.

References

  • 1. Timothy A Yap, Michelle D Garrett, Mike I Walton, Florence Raynaud, Johann S de Bono, Paul Workman. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology, 2008;8:393-412.
  • 2. Weinstein IB, Joe AK: Mechanisms of disease: oncogene addiction — a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
  • 3. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
There are 3 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Review
Authors

Serhan Küpeli 0000-0001-7271-1803

Publication Date March 31, 2022
Acceptance Date January 11, 2022
Published in Issue Year 2022 Volume: 31 Issue: 1

Cite

AMA Küpeli S. Kanserde Hedefe Yönelik Tedavi: PI3K/Akt/mTOR İnhibitörleri. aktd. March 2022;31(1):15-20. doi:10.17827/aktd.1001226